AVM Biotechnology

AVM Biotechnology LLC is a clinical-stage regenerative medicine company based in Seattle, Washington. Founded in 2008, it specializes in the discovery, development, and commercialization of stem cell technologies for applications in regenerative medicine, oncology, and human biologics. The company offers a range of innovative compounds aimed at enhancing organ regeneration and immune system recovery through the modulation of stem cell binding. Its platforms include Boutique Biologics, which focuses on personalized medicine by creating patient-specific biologics that minimize immunogenicity, and Better Biologics, which enables large-scale production of human biologics that address resistance issues. AVM's lead drug, AVM0703, is an advanced formulation of dexamethasone designed to activate the body’s immune cells against cancer, autoimmunity, and infectious diseases. The company is supported by a Scientific Advisory Board comprised of experts in cancer and immunology, and it is engaged in various preclinical development projects, including small molecules and antibody-based candidates.